留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

两性霉素B联合用药的研究进展

赵柳娅 曹颖瑛 姜远英

赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
引用本文: 赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001

两性霉素B联合用药的研究进展

doi: 10.3969/j.issn.1006-0111.2014.01.001

Research progress in the combined use of amphotericin B

  • 摘要: 两性霉素B(amphotericin B,AmB)属于多烯类抗真菌药物,因其耐药率低、抗菌谱广,被称为治疗深部真菌感染的"金标准",但是严重的毒副作用(尤其是肾毒性)大大限制了AmB在临床上的应用。在目前高效、低毒的抗真菌药物较少的情况下,联合使用不同作用机制的抗真菌药物,使其发挥协同作用,缩短疗程、减少药物毒副作用、扩大药物抗菌谱、避免耐药性的出现,是当前深部真菌感染治疗研究领域的一个重要研究方向。本文对AmB与不同种类抗真菌药物联合使用的研究进展作一综述。
  • [1] Montoya JG,Rosso F. Is combination therapy indicated for invasive fungal infections?Yes and no[J].Curr Opin Infect Dis,2006,19(4):371-379.
    [2] Nivoix Y,Zamfir A,Lutun P,et al,Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections[J].J Infect,2006,52(1):67-74.
    [3] Kontoyiannis DP,Lewis RE.Combination chemotherapy for invasive fungal infections:what laboratory and clinical studies tell us so far[J].Drug Resist Updat,2003,6(1):257-269.
    [4] Mukherjee PK,Sheehan DJ,Hitchcock CA,et al.Combination treatment of invasive fungal infections[J].Clin Microbiol Rev,2005,18(1):163-194.
    [5] Chamilos G,Kontoyiannis DP.The rationale of combination antifungal therapy in severely immuncompromised patients:empiricism versus evidence-based medicine[J].Curr Opin Infect Dis,2006,19(4):380-385.
    [6] Marr KA,Boeckh M,Carter RA,et al.Combination antifungal therapy for invasive aspergillosis[J].Clin Infect Dis,2004,39(6):797-802.
    [7] Matsuoka S, Murata M. Cholesterol markedly reduces ion permeability induced by membrane-bound amphotericin B[J]. Biochim Biophys Acta, 2002,1564(2):429-434.
    [8] Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity:a review[J]. J Chemother, 2000,12(6):463-470.
    [9] Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:animal experiments and clinical study[J]. J Infect Dis 2002,186(3):379-388.
    [10] Louie A, Kaw P, Banerjee P,et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis[J].Antimicrob Agents Chemother, 2001, 45(2):485-494.
    [11] Samaranayake YH, Samaranayake LP, Yeung KW. Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J].Chemotherapy, 2001, 47(4):279-291.
    [12] Barchiesi F, Schimizzi AM, Caselli F,et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2000, 44(9):2435-2441.
    [13] Popp AI, White MH, Quadri T,et al. Amphotericin B with and without itraconazole for invasive aspergillosis. A three-year retrospective study[J].Int J Infect Dis, 1999, 3(3):157-160.
    [14] Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species[J].MedMycol, 2001, 39(1):91-95.
    [15] Rodero L, Cordoba S, Cahn, P,et al. In vitro susceptibility studies of Cryptococcus Neoformans isolated from patients with no clinical response to amphotericin B therapy[J].J Antimicrob Chemother,2000, 45(2):239-242.
    [16] Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
    [17] Sevtap Arikan, Mario Lozano-Chiu,Victor Paetznick, et al.In vitro synergy of caspofungin and amphotericin B Against Aspergillus and Fusarium spp[J].Antimicrob Agents Chemother,2002, 46(1):245-247.
    [18] Jon AO, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin[J]. Antimicrob Agents Chemother,2005, 49 (12):4895-4902.
    [19] Francesco B,Elisabetta S,Serena T, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemoth, 2007, 51(3):941-945.
    [20] Ogita A, Hirooka K, Yamamoto Y, et al. Synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, and its relation to the role of alkyl hydroperoxide reductase 1 as a cell surface defense in Saccharomyces cerevisiae[J]. Toxicology,2005,215(3):205-13.
    [21] Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-304.
    [22] An M, Shen H, Cao Y, et al.Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agents. 2009; 33(3):258-63.
    [23] Cao YY,Dai BD, Wang Y, et al.In vitro activity of baicalein against Candida albicans biofilms[J]. Int J Antimicrob Agents, 2008,32:73-77.
    [24] Huang S, Cao YY, Dai BD, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.Biol Pharm Bull, 2011,31:2234-2236.
    [25] Fu ZJ, Lu H,Zhu ZY, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull,2011,34(2):214-218.
    [26] Phillips AJ, Sudbery I, Ramsdale M.Apoptosis induced by environmental stresses and amphotericin B in Candida albicans[J]. Proc Natl Acad Sci,2003,100:14327-14332.
    [27] Phillips AJ, Crowe JD, Ramsdale M.Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans[J].Proc Natl Acad Sci,2006,103:726-731.
    [28] Cao YY,HuangS, Dai BD, et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46:183-189.
    [29] Clancy CJ, Wingard JR, Hong-Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients:review of the literature and demonstration of invitro synergy between antifungal agents[J].Med Mycol, 2000, 38(2):169-175.
    [30] Ellis M, Watson R, McNabb A,et al. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery[J].J Med Microbiol,2002, 51(1):70-75.
  • [1] 孙雨菡, 许子艺, 廖峻, 张翮, 樊莉, 鲁莹.  HPLC法同时测定盐酸阿霉素与氯尼达明的含量 . 药学实践与服务, 2024, 42(3): 127-130. doi: 10.12206/j.issn.2097-2024.202306043
    [2] 万立志, 王境焓, 吴春蓉, 李玲.  基于代谢组学技术的烟酰胺协同两性霉素B抑制白念珠菌的作用机制研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202307034
    [3] 范加腾, 陆峰, 许激扬.  基于D-SERS法表征两性霉素B对白色念珠菌抑制作用的研究 . 药学实践与服务, 2019, 37(2): 156-161,169. doi: 10.3969/j.issn.1006-0111.2019.02.011
    [4] 白向荣, 程红勤, 张雁, 金颖.  两性霉素B膀胱冲洗治疗真菌尿的荟萃分析 . 药学实践与服务, 2018, 36(4): 379-384. doi: 10.3969/j.issn.1006-0111.2018.04.021
    [5] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [6] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [7] 刘丽娜, 刘晓东, 肇丽梅.  1例糖尿病合并侵袭性肺曲霉菌感染患者的药学监护 . 药学实践与服务, 2014, 32(5): 389-392. doi: 10.3969/j.issn.1006-0111.2014.05.022
    [8] 郭凯欣, 石宽, 闻俊, 周婷婷, 范国荣.  唑类抗真菌药物手性分离及药代动力学研究进展 . 药学实践与服务, 2012, 30(6): 418-421. doi: 10.3969/j.issn.1006-0111.2012.06.006
    [9] 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉.  "Polypill"的发展及前景 . 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
    [10] 陈开宇, 江丽萍, 陈盛新.  慢性阻塞性肺疾病的药物治疗进展 . 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
    [11] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [12] 胡宏岗, 赵庆杰, 张俊, 吴秋业, 刘超美, 徐建明.  抗真菌药物作用靶位的研究进展 . 药学实践与服务, 2005, (2): 65-71.
    [13] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [14] 尹玉琴, 王根春, 李崇映, 李春东, 徐贵丽.  5种抗真菌药物的体外敏感性试验 . 药学实践与服务, 2004, (2): 79-80.
    [15] 曹琴, 范伟, 王凯伟.  抗真菌药物的研究进展和临床应用 . 药学实践与服务, 2003, (4): 225-228.
    [16] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
    [17] 罗东, 马文秀, 代青, 刘松青.  HPLC法测定两性霉素B含量 . 药学实践与服务, 1998, (3): 166-168.
    [18] 王晓明, 张紫洞.  两性霉素B溶液治疗鹅口疮 . 药学实践与服务, 1989, (3): 56-56.
    [19] 丁祯禄, 冯仰华.  两性霉素B和多粘菌素B相互作用的实验研究 . 药学实践与服务, 1985, (2): 79-79.
    [20] 李国秀, 于文英.  联合用药处方调查及分析 . 药学实践与服务, 1984, (3): 28-31.
  • 加载中
计量
  • 文章访问数:  2048
  • HTML全文浏览量:  265
  • PDF下载量:  126
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-03-12
  • 修回日期:  2013-09-02

两性霉素B联合用药的研究进展

doi: 10.3969/j.issn.1006-0111.2014.01.001

摘要: 两性霉素B(amphotericin B,AmB)属于多烯类抗真菌药物,因其耐药率低、抗菌谱广,被称为治疗深部真菌感染的"金标准",但是严重的毒副作用(尤其是肾毒性)大大限制了AmB在临床上的应用。在目前高效、低毒的抗真菌药物较少的情况下,联合使用不同作用机制的抗真菌药物,使其发挥协同作用,缩短疗程、减少药物毒副作用、扩大药物抗菌谱、避免耐药性的出现,是当前深部真菌感染治疗研究领域的一个重要研究方向。本文对AmB与不同种类抗真菌药物联合使用的研究进展作一综述。

English Abstract

赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
引用本文: 赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
参考文献 (30)

目录

    /

    返回文章
    返回